Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit.
Journal
European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
25
12
2018
accepted:
17
01
2019
pubmed:
4
2
2019
medline:
7
10
2020
entrez:
4
2
2019
Statut:
ppublish
Résumé
Results from the ERA 223 trial of abiraterone combined with radium-223 among men with chemotherapy-naïve castration-resistant prostate cancer and bone metastases show no improvement in survival free from symptomatic skeletal events. We hypothesize that this finding might be attributable to bone loss induced by the concomitantly administered prednisone.
Identifiants
pubmed: 30711330
pii: S0302-2838(19)30069-7
doi: 10.1016/j.eururo.2019.01.026
pii:
doi:
Substances chimiques
Androstenes
0
Radium-223
8BR2SOL3L1
Abiraterone Acetate
EM5OCB9YJ6
abiraterone
G819A456D0
Prednisone
VB0R961HZT
Radium
W90AYD6R3Q
Types de publication
Editorial
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
894-895Commentaires et corrections
Type : CommentOn
Informations de copyright
Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.